Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient

Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.

• Source: Shutterstock

Sanofi could try to differentiate Zantac 360 among histamine-2 blockers in the OTC heartburn remedy category by qualifying and modifying its “#1 doctor recommended” claim that an industry self-regulation group’s appeals panel says it didn’t support.

The French firm asked BBB National Programs Inc.’s National Advertising Review Board to consider using a claim of “#1 doctor...

More from Marketing & Advertising

More from Business

Haleon Takes Full Control Of China JV

 
• By 

Haleon finalizes deal to make its China joint venture a wholly-owned subsidiary in move to "drive category growth in one of the fastest growing OTC markets globally."

Perrigo Combines Americas, International Leads Into Global Post In Latest Move To Boost Results

 

Roberto Khoury, Perrigo’s international lead for a year, moves to CCO while his counterpart for the Americas region appointed in September 2023, Catherine "Triona" Schmelter, is leaving with her post eliminated in the firm’s changes.

Scope Launches Eyelid-Friendly Eye Cream In The UK

 
• By 

Eyelids have the "thinnest, most sensitive skin on the body" and are "highly prone to dehydration," which is why Scope has launched new Optase Life Sensitive Eye Daily Renewal Cream.